Tag: Biomed

 Biomed Industries, Inc. (Biomed) announced today that it has developed a promising obesity drug, NA-921, which is poised for Phase 2/3 clinical trials. NA-921 is a small molecule drug available in oral formulation. The Company is in discussions with potential partners for collaboration on a Phase 3 trial of NA-921, a promising candidate for treatment of diabetic obesity. The drug is a once-a-day oral capsule based on a novel mechanism of action of GLP-1 and IGF-1 for which the Company has recently filed for patent protection. Its analogue/prodrug has already been approved by the FDA for a certain rare disease, ... Read more

 Biomed Industries, Inc. (“BIOMED” or the “Company”) announced that it has entered into a definitive share exchange agreement on September 16, 2022 with MedAware Systems, Inc. (“MedAware”) for the acquisition of all of the issued and outstanding shares of MedAware (the “Transaction”). The Boards of Directors of BIOMED and MedAware have each approved the Share Exchange, pursuant to which all of the rights, titles and interests of all issued and outstanding of common shares of capital stock of MedAware will be exchanged for common stock of BIOMED at a ratio of 5.34 shares of MedAware for 1 new common share ... Read more